Viridian Therapeutics, Inc. $VRDN Shares Purchased by Hennion & Walsh Asset Management Inc.

Hennion & Walsh Asset Management Inc. raised its position in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) by 19.6% in the second quarter, Holdings Channel.com reports. The fund owned 209,092 shares of the company’s stock after buying an additional 34,198 shares during the quarter. Hennion & Walsh Asset Management Inc.’s holdings in Viridian Therapeutics were worth $3,841,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in VRDN. ANTIPODES PARTNERS Ltd acquired a new position in shares of Viridian Therapeutics in the 4th quarter valued at about $36,000. KBC Group NV purchased a new stake in shares of Viridian Therapeutics during the 1st quarter worth about $34,000. Larson Financial Group LLC acquired a new stake in Viridian Therapeutics during the 3rd quarter worth approximately $52,000. US Bancorp DE increased its position in Viridian Therapeutics by 23.2% during the 3rd quarter. US Bancorp DE now owns 2,457 shares of the company’s stock worth $53,000 after purchasing an additional 463 shares in the last quarter. Finally, State of Wyoming purchased a new position in Viridian Therapeutics in the first quarter valued at approximately $93,000.

Viridian Therapeutics Stock Performance

Shares of VRDN stock opened at $23.06 on Tuesday. Viridian Therapeutics, Inc. has a 12 month low of $13.18 and a 12 month high of $34.29. The company has a debt-to-equity ratio of 0.10, a current ratio of 15.15 and a quick ratio of 15.15. The firm has a market capitalization of $2.61 billion, a P/E ratio of -6.84 and a beta of 0.91. The company’s fifty day moving average price is $18.51 and its two-hundred day moving average price is $21.52.

Viridian Therapeutics (NASDAQ:VRDN) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($1.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.03) by ($0.02). The firm had revenue of $0.28 million during the quarter, compared to analysts’ expectations of $0.06 million. Viridian Therapeutics had a negative net margin of 505.86% and a negative return on equity of 76.65%. On average, research analysts anticipate that Viridian Therapeutics, Inc. will post -4.02 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have weighed in on the stock. Stifel Nicolaus set a $39.00 price target on shares of Viridian Therapeutics in a research report on Wednesday, May 13th. Truist Financial increased their price objective on shares of Viridian Therapeutics from $38.00 to $39.00 and gave the stock a “buy” rating in a research report on Friday. The Goldman Sachs Group reissued a “buy” rating and issued a $39.00 target price on shares of Viridian Therapeutics in a research note on Tuesday, June 30th. Evercore set a $26.00 target price on shares of Viridian Therapeutics in a report on Friday, May 15th. Finally, Wells Fargo & Company raised shares of Viridian Therapeutics from an “equal weight” rating to an “overweight” rating and upped their price target for the stock from $20.00 to $31.00 in a research report on Monday, June 29th. Thirteen research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $38.93.

About Viridian Therapeutics

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.